A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

Exclusion Criteria

• •Monogenic disorder pertaining to infant onset Inflammatory Bowel Disease (IBD)
• •History of \>= 3 bowel resections: \> 2 missing segments of the following five segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum
• •Current diagnosis of ulcerative colitis (UC), abdominal/intraabdominal/perianal fistula and/or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease.
• •Symptomatic bowel strictures, fulminant colitis, or toxic megacolon
• •Presence of abdominal or perianal abscess
• •Current diagnosis or suspicion of primary sclerosing cholangitis